Needham & Company Starts AtriCure Inc. (ATRC) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Dougherty & Co Starts AtriCure Inc. (ATRC) at Buy
March 11, 2015 6:52 AM EDTDougherty & Co initiates coverage on AtriCure Inc. (NASDAQ: ATRC) with a Buy rating and a price target of $25.00. Analyst Charley Jones noted accelerating growth, and he thinks the company is likely to be acquired.
"ATRC is the technology and market share leader of the surgical atrial fibrillation (AF) and Left Atrial Appendage (LAA) markets, which we estimate will grow... More
